The Effect of Magnesium Citrate on %FEV1, %PEFR, and Asthma Control Test Score in Patients with Controlled Asthma and Uncontrolled Asthma
DOI:
https://doi.org/10.36497/jri.v45i3.503Abstract
Background: Asthma is one of the most common non-communicable diseases in the world and affected an estimated 262 million people in 2019. Magnesium is one of the nutrients known to improve lung function in asthma by inhibits production of proinflammatory cytokines, exhibits anti-inflammatory benefits, and has beneficial muscle relaxation and bronchodilating effects. Measurement of %FEV1, %PEFR, and ACT score are indicators of lung function. Magnesium citrate may be used as an adjunct therapy in patients with controlled and uncontrolled asthma.
Methods: Clinical trial research with quasi experimental method using a pretest and posttest design. The number of study subjects was 34 controlled and uncontrolled asthma patients at outpatient clinic Universitas Sebelas Maret Hospital and dr. Soehadi Prijonegoro Hospital in February - March 2023 by means of consecutive sampling. The control group (n=17) received standard therapy while the treatment group (n=17) received standard therapy plus 300 mg magnesium citrate for 42 days. Serum magnesium level, %FEV1, %PEFR, and ACT score were measured at enrollment and on the fourty third day of treatment.
Results: There were significant differences between the treatment group compared to the control group in increasing %PEFR (p = 0.001), increasing ACT score (p = 0.011), and increasing %FEV1 (p = 0.071).
Conclusion: Administration of magnesium citrate to patients with controlled asthma and uncontrolled asthma can increase levels of %PEFR, ACT score, and %FEV1.
Keywords: magnesium citrate, %FEV1, %PEFR, ACT, asthmaDownloads
Published
Issue
Section
License
Copyright (c) 2025 Anang Purwoko Atmojo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
